Tumor-infiltrating dendritic cells (DC) highly express TIM3, which can compete with nucleic acid binding to its ligand high-mobility group protein B1 (HMGB1), reducing anti-tumor immunity otherwise mediated by nucleic acids (67). This evidence concerns the gene HAVCR2 and neoplasm.